Trial Profile
A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-523 in Patients With Relapsed or Refractory Hematologic Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Sep 2022
Price :
$35
*
At a glance
- Drugs Sovleplenib (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Adverse reactions
- Sponsors Hutchison MediPharma; HUTCHMED
- 10 Sep 2020 Status changed from recruiting to active, no longer recruiting.
- 22 Feb 2019 Planned number of patients changed from 67 to 78.
- 22 Feb 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Dec 2020.